M. Fontanillas

发表

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer

D. Fuster, F. Lomeña, P. Fernández, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Tyrosinase m RNA i n B lood o f P atients W ith M elanoma Treated W ith A djuvant I nterferon

D. Colomer, B. Mellado, N. Reguart, 2002 .

Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon.

D. Colomer, B. Mellado, N. Reguart, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).

J. Garcia-conde, J. S. San Miguel, J. Hernández, 1992, European journal of cancer.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

J. S. San Miguel, J. Ribera, J. Bladé, 2005, Blood.

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology)

E. Montserrat, J. Garcia-conde, J. Bladé, 1998, Leukemia.

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.

E. Montserrat, J. Garcia-conde, J. Maldonado, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients.

D. Colomer, B. Mellado, L. Gutierrez, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment of multiple myeloma in elderly people: long-term results in 178 patients.

E. Montserrat, J. Garcia-conde, J. Maldonado, 1996, Age and ageing.

Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials

E. Kimby, F. Bosch, E. Montserrat, 1999 .

CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial

A. López-Guillermo, E. Montserrat, J. Garcia-conde, 1996, European journal of haematology.

Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.

A. Oriol, J. Besalduch, J. S. San Miguel, 2001, Haematologica.

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.

J. Garcia-conde, J. Hernández-Rivas, A. Oriol, 1998, Haematologica.

Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93

M. Terol, J. Garcia-conde, J. Miguel, 1998 .

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Mike Clarke, K Wheatley, A Riccardi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].

A. López-Guillermo, E. Montserrat, J. Garcia-conde, 1998, Medicina clinica.

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

J. Esteve, E. Montserrat, J. Garcia-conde, 2001, The hematology journal : the official journal of the European Haematology Association.

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

M. Fontanillas, F. Carabantes, J. Illarramendi, 2018, Clinical and Translational Oncology.

PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.

D. Fuster, K. Skaltsa, F. Lomeña, 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.

D. Fuster, G. Santamaría, M. Velasco, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89)

A. Oriol, E. Feliú, M. Fontanillas, 1998 .